Alzheimer's Disease
Conditions
Keywords
apolipoprotein E, Alzheimer's disease, cognition, rosiglitazone, adjunctive therapy
Brief summary
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer's disease (AD) when combined with the currently approved AD medication, Aricept (donepezil). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one's genetic makeup affects their response to the study drug. Clinical data suggesting that RSG may benefit AD patients was first seen in a small study performed at the University of Washington and then from a larger GSK study conducted in Europe and New Zealand. In the first study, subjects receiving RSG once daily for 6 months scored significantly better on 3 tests of memory and thought than those who did not receive RSG. In the GSK study, those that appeared to benefit most from treatment with RSG XR had a specific genetic pattern. They did not have the gene that caused them to produce the protein apolipoprotein E e4 (APOE e4). Subjects who have the APOE e4 gene may have two copies, one from each parent, or they may have only one APOE e4 gene meaning that they inherited either the APOE e2 or APOE e3 version of the gene, instead of APOE e4, from one of their parents. Subjects with one copy of the APOE e4 gene remained at their same level of thinking ability while those with two copies of the APOE e4 gene, continued to worsen during the 6-month treatment. The current study will more directly test the effectiveness or RSG XR on people who either have or lack the APOE e4 gene.
Detailed description
A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer's disease (REFLECT-2)
Interventions
Rosiglitazone Extended Release 2mg OD
Rosiglitazone Extended Release 8mg OD
OTHERPlacebo
Placebo
OTHERDonepezil
Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* A subject will be eligible for inclusion in this study only if all of the following criteria apply: * Male or female subject with a clinical diagnosis of probable Alzheimer's disease in accordance with NINCDS-ADRDA criteria. (Note: National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related Disorders Association (ADRDA).) * Subject has mild to moderate Alzheimer's disease as defined by a MMSE score 10 to 26 inclusive at Screening. * Hachinski Ischemia Score ≤ 4 at Screening. * Age ≥50 and ≤90 years. * At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study). * Current use of medication is in accordance with the criteria listed in Table 2 (Permitted Medications,). * Female subjects must be post-menopausal (i.e. \>1 year without menstrual period), surgically sterile, or agree to use adequate method of contraception for the duration of the study. Female subjects who are pre-menopausal or who have been post-menopausal for \<1 year must undertake pregnancy testing (urine test) at Visit 1, which must be negative. * Brain CT or MRI scan performed within the past 12 months or at Screening, showing no evidence of any other potential cause of dementia other than Alzheimer's disease. (Note: Questionable CT or MRI scans should be discussed with the medical monitor, using central imaging guidelines.) * Neurological exam without focal changes (excluding changes attributable to AD or peripheral trauma). * Subject has the ability to comply with procedures for cognitive and other testing. * Subject lives with (or has substantial periods of contact with) a regular caregiver who is willing to attend all visits, oversee the subject's compliance with protocol-specified procedures and study medication, and report on subject's status. Note: A non-cohabiting caregiver must spend sufficient time with the subject so that, in the opinion of the Investigator, the caregiver can reliably assess cognitive function, activities and behavior, and report on the subject's compliance and health. As caregiver time spent with a potential subject is anticipated to be highly variable across countries and cultures, GSK will consider a variety of different measures by which this stipulation may be met, and GSK should be consulted if adequacy of a caregiver situation is in doubt. However, as guidance, the ability for a caregiver to meet his/her expected responsibilities for this study would normally be possible when the caregiver spends no less than 10 hours per week with the subject, divided over multiple days.) * Subject has provided full written informed consent prior to the performance of any protocol-specified procedure; or if unable to provide informed consent due to cognitive status, full written informed consent on behalf of the subject has been provided by a legally acceptable representative. (Note: Consent by legally acceptable representative is allowed where this is in accordance with local laws, regulations and ethics committee policy.) * Caregiver has provided full written informed consent on his/her own behalf prior to the performance of any protocol-specified procedure. * Subjects considered for enrolment must have a QTc (either QTc B (Bazett's correction) or QTc F (Fridericia's correction)) \<450msec at Visit 1, with the exception of subjects with bundle branch block (for whom either QTc B or QTc F must be \<480msec). * (Note: For the purposes of these criteria, QTc B is defined as (QT interval \[msec\]) / (square root of RR interval \[seconds\]); and QTc F is defined as (QT interval \[msec\]) / (cube root of RR interval \[seconds\]).)
Exclusion criteria
* A subject will not be eligible for inclusion in this study if any of the following criteria apply: * Diagnosis of possible, probable, or definite vascular dementia in accordance with NINDS-AIREN criteria. (Note: National Institute of Neurological Disorders and Stroke (NINDS) and Association Internationale pour la Recherche et l'Enseignement en Neurosciences (AIREN).) * History or evidence of any other CNS disorder that could be interpreted as a cause of dementia: e.g. cerebrovascular disease (stroke, hemorrhage), structural abnormality, epilepsy, infectious or inflammatory/demyelinating CNS conditions, Parkinson's disease. * Evidence of the following disorders: current vitamin B12 deficiency, positive syphilis serology, or active thyroid dysfunction (particularly that suggestive of hypothyroidism), including abnormally high or low serum levels of thyroid stimulating hormone (TSH) that are clinically significant in the opinion of the investigator. (Note: Testing is required for each parameter only when no result is available from previous 12 months.) * History of Type 1 diabetes mellitus or secondary diabetes mellitus. * Type 2 diabetes mellitus where the subject is being treated with insulin, a PPARγ agonist, or an insulin secretagogue (e.g. a sulfonylurea or glitinide). * Any patient with an HbA1c ≥8.5%. (See Section 6.3.7.4 for Safety Measures for Enrolled Subjects with Type 2 Diabetes Mellitus.) * History or clinical/investigational evidence of congestive heart failure defined by the New York Heart Association criteria (Class I to IV cardiac status;). * History of cardiovascular event within the last 6 months (i.e. intervention, percutaneous coronary intervention, vascular surgery, acute coronary syndrome \[non Q-wave myocardial infarction, Q-wave myocardial infarction, unstable angina\] or significant arrhythmia; or major intervention (e.g. cardiac surgery or angiography plus stenting) scheduled). * History of significant psychiatric illness such as schizophrenia or bipolar affective disorder that in the opinion of the Investigator would interfere with participation in the study, major depressive disorder (according to DSM-IV) in the past year, or current active depression requiring initiation of treatment. (Note: If not currently treated, but active depression is suspected, the Cornell Scale for Depression in Dementia (CSDD) can be used by the Investigator as a guide for deciding whether a prospective subject requires treatment. If the subject has a CSDD score \>7, the Investigator should decide if the subject has depression in need of prescribed medication, and a CSDD \>12 is considered a strong indicator that treatment is needed. Subjects will be allowed to re-screen after their depression has been adequately managed for \>3 months.) * History or presence of gastro-intestinal, hepatic, or renal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, or any other clinically relevant abnormality, medical or psychiatric condition, which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study. * Clinically significant peripheral edema at the time of screening. * Current or recent drug or alcohol abuse or dependence (defined by DSM-IV criteria for substance-related disorders), or recent or remote history of the same if that could be a contributing factor to the dementia. * Systolic blood pressure \>165 or \<90 mmHg or diastolic blood pressure \>95 or \<60 mmHg at the time of screening. * Clinically significant anemia (i.e. hemoglobin \<11 g/dL for males or \<10 g/dL for females) or presence of hemoglobinopathies which would prevent accurate assessment of HbA1c. * Abnormal kidney function tests (\>1.5 the upper limit of normal (ULN)). * ALT, AST, or alkaline phosphatase values \>2.5 times the ULN, total bilirubin values \>1.5 times the ULN, or history of severe hepatobiliary disease (e.g. hepatitis B or C, or cirrhosis, Child-Pugh Class B/C). (Note: For subjects with a diagnosis of Gilberts Syndrome and an isolated increase in total bilirubin \>1.5 ULN, fractionation should be performed. If all of the following conditions are met, the patient may enter or remain in the study, even if total bilirubin \>1.5 ULN: * an elevated unconjugated (indirect) bilirubin; * the percentage of direct bilirubin \<35%; * ALT, AST, and alkaline phosphatase \<2.5 ULN if subject is in screening (\<2.0 ULN for Canadian subjects only), or ≤3 ULN if subject is already randomized into the study) * History of a bone marrow transplant. * Subject is unable (with assistance, if appropriate) to take study medication as prescribed throughout the study or is at risk of non-compliance with study medication or procedures. * Subject is an immediate family member or employee of the participating Investigator, of any of the participating site staff, or of GSK. * In France, a subject is neither affiliated with nor a beneficiary of a social security category. * The French subject has participated in any study using an investigational drug during the previous 30 days or 5 half-lives (whichever is longer). * Cognitive tasks prescribed for cognitive rehabilitation and performed under medical supervision are prohibited for 6 months prior to Screening, as well as for the duration of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48 | Baseline (Week 0) and Week 48 | ADAS is a performance-based test that measures specific cognitive and behavioral dysfunctions in participants with Alzheimer's Disease. The cognitive subscale of the ADAS (ADAS-Cog) comprises 11 items that are summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. Change from baseline is calculated as Week 48 value minus the baseline value. APOE4 negative, All except E4/E4's: comprised of APOE4 negative and E4 heterozygote and full population was analyzed for this outcome measure. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the genetic subgroups. Least square mean is entered for adjusted mean. |
| Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4 | Baseline (Week 0) and Week 48 | CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Change from baseline is calculated as Week 48 value minus the baseline value. APOE4 negative, All except E4/E4's: comprised of APOE4 negative and E4 heterozygote and full population was analyzed for this outcome measure. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the genetic subgroups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Screening in Mini Mental State Examination (MMSE) Total Score | Screening (Week -4) and Week 48 | The MMSE consists of 11 tests of orientation, memory (recent and immediate), concentration, language and praxis. The scale was completed by the investigator, based on the performance of the participant, and took approximately 5 to 10 minutes to administer. The scores from 11 tests were combined to obtain the total score. The total scores range from 0 to 30, with lower scores indicating greater cognitive impairment and higher score indicating better outcome; a positive change from screening indicated an improvement. The total MMSE score for participants at screening was between 10 and 26, inclusive, in order to be eligible to participate in the trial. Change from screening is calculated as endpoint value minus the screening value. |
| Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Baseline (Week 0), Week 12, 24, 36 and 48 | The RUD instrument was developed as a comprehensive tool to assess the amount of resource use among demented patients. RUD assessd both formal and informal resource use of the patient and the primary caregiver, making it possible to calculate costs from a societal perspective. Q1 corresponds to the number of hours during the last month the caregiver spent assisting the patient with toilet visits, eating, dressing, grooming, walking and bathing and Q2 corresponds to the number of hours during the last month the caregiver spent assisting the patient with shopping, food preparation, housekeeping, laundry, transportation, taking medication and managing financial matters. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. |
| Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Baseline (Week 0), Week 12, 36 and 48 | The EQ-5D Proxy is a two part scale that evaluated the participant's health status via Thermometer and Utility scores. The Thermometer score was the caregiver's rating of the participant's overall health status on a VAS (0 \[worst possible status\] to 100 \[best imaginable status\]). The Utility score was a caregiver rating of health status on dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression\] where '1' indicated better health state (no problems); '3' indicated worst health state (confined to bed). Total possible score was the sum of individual items, ranged from 5 to 15; lower score indicated a better health state and higher score indicated greater severity of symptoms. A positive change from baseline indicated improvement in the Thermometer score and a negative change from baseline indicated improvement in the Utility score. Change from baseline is calculated as endpoint value minus the baseline value. |
| Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Baseline (Week 0), Week 8, 16, 24, 36 and 48 | ADAS is a performance-based test that measures specific cognitive and behavioral dysfunctions in patients with Alzheimer's Disease. The cognitive subscale of the ADAS (ADAS-Cog) comprises 11 items that are summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. Change from baseline is calculated as endpoint value minus the baseline value. |
| Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48 | Baseline (Week 0), Week 12, 24, 36 and 48 | CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Change from baseline is calculated as endpoint value minus the baseline value. |
| Change in ADAS-Cog Total Score for Observed Cases at Week 54 Compared to Week 48 | Week 48 and 54 | ADAS is a performance-based test that measures specific cognitive and behavioral dysfunctions in patients with Alzheimer's Disease. The cognitive subscale of the ADAS (ADAS-Cog) comprises 11 items that are summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. Change was calculated as endpoint value (Week 54) minus Week 48 value. |
| Change in CDR-SB Total Score at Week 54 Compared to Week 48 | Week 48 and 54 | CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Change was calculated as endpoint value (Week 54) minus Week 48 value. |
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 48 | Baseline (Week 0) and Week 48 | Blood samples of participants were collected for HbA1c assessment. HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. Change from Baseline in HbA1c was calculated as the value at Week 48 minus the value at Baseline. |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to Week 54 | An adverse event (AE) was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. The data was reported for prospective period. |
| Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score | Baseline (Week 0), Week 8, 16, 24 and 48 | The DAD measures instrumental and basic activities of daily living in participants with Alzheimer's Disease (AD). This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. The scale includes 23 items relating to instrumental activities of daily living and 17 items relating to basic self-care. Each item can be scored as 1 = yes, 0 = no, non applicable = NA. Total score was obtained by adding the rating for each question and converting this total score out of 100. The total score ranged from 0 to 100, where higher score indicated better function and lower score indicated greater severity of symptoms; a positive change from baseline indicated an improvement. Change from baseline is calculated as endpoint value minus the baseline value. |
| Mean Change From Baseline in Heart Rate | Baseline (Week 0), Week 4, 8, 12, 16, 24, 36, 48 and 56 | Mean Change From Baseline in heart rate was calculated as endpoint value minus the baseline value. |
| Mean Change From Baseline in Weight | Baseline (Week 0), Week 4, 8, 12, 16, 24, 36, 48 and 56 | Body weight was measured at all visits, without shoes and wearing light clothing. Mean Change From Baseline in Weight was calculated as endpoint value minus the baseline value. |
| Change From Baseline in Hemoglobin Values | Baseline (Week 0), Week 4, 16, 36 and 48 | Blood samples of participants were collected for Hemoglobin. Change from baseline in Hemoglobin was calculated as endpoint value minus the baseline value. |
| Change From Baseline in Hematocrit Values | Baseline (Week 0), Week 4, 8, 12, 16, 36 and 48 | Blood samples of participants were collected for Hematocrit . Change from baseline in Hematocrit was calculated as endpoint value minus the baseline value. |
| Change From Baseline in HbA1c at Week 12, Week 24 and Week 36 | Baseline (Week 0) and Week 12, 24 and 36 | Blood samples of participants were collected for HbA1c assessment. HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. Change from Baseline in HbA1c was calculated as the value at time point minus the value at Baseline. |
| Mean Change From Baseline in Short Term Memory Assessment Score | Baseline (Week 0), Week 8, 16, 24, 36, 48 and 56 | Short term memory assessment score was based on ADAS-Cog questionnaire (Question 1 and 7). ADAS is a performance-based test that measures specific cognitive and behavioral dysfunctions in participants with AD. Question 1 (Word Recall) and Question 7 (Word Recognition) of the ADAS-Cog questionnaire were summed to get a short term memory assessment score. Word recall task consist of the participants score was the mean number of words not recalled on three trials (maximum score 10) and word recognition task, to score this item the number of incorrect responses was counted (maximum error score was 12). The total score ranged from 0 to 22 with 0 indicating absence of symptoms and higher scores indicating greater dysfunction; a negative change from baseline indicated improvement. Change from Baseline in short term memory assessment was calculated as endpoint value minus the baseline value. |
| Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Baseline (Week 0), Week 4, 8, 12, 16, 24, 36, 48 and 56 | Only those parameters for which at least one value of clinical concern (CC) was reported are summarized. Pre-defined limits of potential clinical concern (CC Low \[relative to the lower limit of normal\], CC High \[relative to the upper limit of normal\]) are: Hematocrit 0.8, 1.2; hemoglobin 10-11, 16.5-18; Red blood corpuscles(RBC) 0.8, 1.2; mean corpuscular volume (MCV) 0.8, 1.2; mean corpuscular hemoglobin (MCH) 0.8, 1.2; White blood corpuscles (WBC) 3- absolute value, 15-absolute value, Red Cell Distribution Width (RDW) 0.8, 1.2; Lymphocytes 0.75, 1.5; Monocytes NA, 2; Eosinophil NA, 2; platelet count 100-absolute, 500-absoulte; segmented neutrophil (SN) 0.75, 1.5 and Total Neutrophil (TN) 0.75, 1.5. |
| Change From Baseline in Alzheimer's Carer Quality of Life Instrument (ACQLI) Total Score | Baseline (Week 0), Week 12, 36 and 48 | The ACQLI was an assessment of caregiver quality of life. This instrument consists of 30 questions exploring various aspects of carer's quality of life. Each of the questions had a two point response and the 30 questions were summed to provide a total score. Items are assumed to be unidimensional (i.e., represent a single variable) and are scored 0/1 (false/true) before summation into a total score with a 0-30 range. The total score ranged from 0 to 30, where 0 indicated absence of symptoms and higher score indicated worse outcomes; a negative change from baseline indicated improvement. Change from baseline was calculated as endpoint value minus the baseline value. |
| Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Baseline (Week 0), Week 4, 8, 12, 16, 24, 36, 48 and 56 | The plethysmographic method was used to measure BP throughout the study. Change in Systolic and Diastolic BP was calculated as endpoint value minus the baseline value. |
| Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | Baseline (Week 0), Week 8, 16, 24 and 48 | The NPI is a questionnaire that quantifies behavioral changes in dementia. For each of 12 behavioral domains there are 4 scores: Frequency (scale:1=occasionally to 4=very frequently), Severity (scale:1=Mild to 3=Severe), Total (frequency x severity), Caregiver distress (scale: 0=not at all distressing to 5=extremely distressing).The NPI Psychosis Subscale consists of the two domains of Delusions and Hallucinations, calculated by adding the Individual Item Scores, to yield a possible total score of 0 to 24. Lower score=less severity. Change from baseline is calculated as endpoint value minus the baseline value. |
Countries
Argentina, Austria, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Italy, Japan, Mexico, Poland, Portugal, Spain, Switzerland, United States
Participant flow
Recruitment details
The study was conducted on participants with mild to moderate Alzheimer's disease(AD), who received donepezil for at least 6 months and who received a stable dose of donepezil for at least 2 months immediately before study entry from 06 July 2006 to 28 January 2009 across 228 centers of 19 countries.
Pre-assignment details
A total of 1496 participants were randomized for the study, out of which seventeen participants did not receive study medication. A total of 1479 were included in the Safety population.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Participants received rosiglitazone extended release matching placebo tablet orally, once daily until Week 54. | 496 |
| 2mg Rosiglitazone Extended Release Participants received rosiglitazone extended release 2 milligram (mg) tablet orally, once daily until Week 48 followed by placebo tablet orally once daily until Week 54. | 494 |
| 8mg Rosiglitazone Extended Release Participants received rosiglitazone extended release 4 mg tablet orally, once daily until Week 4 followed by 8 mg tablet orally once daily from Week 4 until Week 48 followed by placebo tablet orally once daily until Week 54. | 489 |
| Total | 1,479 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 56 | 28 | 63 |
| Overall Study | Adverse event not attended | 0 | 0 | 1 |
| Overall Study | A foul of exclusion criteria | 0 | 1 | 0 |
| Overall Study | Cardiologist recommendations | 0 | 0 | 1 |
| Overall Study | Caregiver sick | 1 | 0 | 0 |
| Overall Study | Caregiver withdrawal | 3 | 0 | 7 |
| Overall Study | Cognitive and behaviour worsening | 2 | 0 | 0 |
| Overall Study | Death of caregiver | 1 | 0 | 1 |
| Overall Study | Decision of sponsor | 1 | 0 | 0 |
| Overall Study | Did not appear in time for Visit 3 | 1 | 0 | 0 |
| Overall Study | ECG abnormal | 0 | 0 | 2 |
| Overall Study | Forgot often medication | 0 | 1 | 0 |
| Overall Study | HCV career | 0 | 0 | 1 |
| Overall Study | Increased dose of Aricept | 0 | 0 | 1 |
| Overall Study | Ineffectiveness of treatment | 0 | 1 | 0 |
| Overall Study | Lack of insight, dementia | 1 | 0 | 0 |
| Overall Study | Lost to Follow-up | 6 | 7 | 4 |
| Overall Study | Medical Monitor decision | 0 | 0 | 1 |
| Overall Study | No disponibility of medication | 1 | 0 | 0 |
| Overall Study | Non-compliance | 8 | 6 | 8 |
| Overall Study | Participant died | 2 | 1 | 1 |
| Overall Study | Participant was hospitalized | 0 | 1 | 0 |
| Overall Study | PI closing medical practice | 1 | 0 | 0 |
| Overall Study | Principal investigator's decision | 1 | 0 | 0 |
| Overall Study | Protocol Violation | 7 | 12 | 7 |
| Overall Study | Site closure | 0 | 0 | 1 |
| Overall Study | Sponsor refuseal | 0 | 1 | 1 |
| Overall Study | Unable to complete ET visit | 1 | 0 | 0 |
| Overall Study | Use of prohibited medication | 5 | 2 | 2 |
| Overall Study | Withdrawal by Subject | 33 | 37 | 40 |
| Overall Study | Worsened neurodegenerative disease | 1 | 0 | 0 |
| Overall Study | Worsening of alzheimer | 1 | 0 | 1 |
| Overall Study | Wrong bottle allocated | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | Placebo | 2mg Rosiglitazone Extended Release | 8mg Rosiglitazone Extended Release | Total |
|---|---|---|---|---|
| Age, Continuous | 74.2 Years STANDARD_DEVIATION 7.95 | 74.5 Years STANDARD_DEVIATION 8.06 | 74.4 Years STANDARD_DEVIATION 7.83 | 74.4 Years STANDARD_DEVIATION 7.94 |
| Race/Ethnicity, Customized Hispanic or Latino | 97 Participants | 86 Participants | 82 Participants | 265 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 399 Participants | 408 Participants | 407 Participants | 1214 Participants |
| Sex: Female, Male Female | 304 Participants | 286 Participants | 305 Participants | 895 Participants |
| Sex: Female, Male Male | 192 Participants | 208 Participants | 184 Participants | 584 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 12 / 496 | 6 / 494 | 8 / 489 |
| other Total, other adverse events | 11 / 496 | 29 / 494 | 69 / 489 |
| serious Total, serious adverse events | 62 / 496 | 45 / 494 | 50 / 489 |
Outcome results
Primary
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48
ADAS is a performance-based test that measures specific cognitive and behavioral dysfunctions in participants with Alzheimer's Disease. The cognitive subscale of the ADAS (ADAS-Cog) comprises 11 items that are summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. Change from baseline is calculated as Week 48 value minus the baseline value. APOE4 negative, All except E4/E4's: comprised of APOE4 negative and E4 heterozygote and full population was analyzed for this outcome measure. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the genetic subgroups. Least square mean is entered for adjusted mean.
Time frame: Baseline (Week 0) and Week 48
Population: ITT population included all the participants who were randomized to treatment, who had received at least one dose of study medication and who had at least one post baseline efficacy assessment. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48 | All except E4/E4s | 3.1 Score on a scale | Standard Error 0.36 |
| Placebo | Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48 | APOE4 negatives | 2.9 Score on a scale | Standard Error 0.54 |
| Placebo | Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48 | Full populations | 3.4 Score on a scale | Standard Error 0.35 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48 | All except E4/E4s | 2.1 Score on a scale | Standard Error 0.29 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48 | APOE4 negatives | 1.6 Score on a scale | Standard Error 0.42 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48 | Full populations | 2.4 Score on a scale | Standard Error 0.3 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48 | APOE4 negatives | 2.7 Score on a scale | Standard Error 0.56 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48 | Full populations | 3.2 Score on a scale | Standard Error 0.35 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48 | All except E4/E4s | 3.1 Score on a scale | Standard Error 0.37 |
p-value: 0.04995% CI: [-2.7, 0]Mixed Models Analysis
p-value: 0.80895% CI: [-1.7, 1.3]Mixed Models Analysis
p-value: 0.03595% CI: [-1.9, -0.1]Mixed Models Analysis
p-value: 0.99995% CI: [-1, 1]Mixed Models Analysis
p-value: 0.0295% CI: [-1.9, -0.2]Mixed Models Analysis
p-value: 0.66195% CI: [-1.2, 0.7]Mixed Models Analysis
Primary
Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4
CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Change from baseline is calculated as Week 48 value minus the baseline value. APOE4 negative, All except E4/E4's: comprised of APOE4 negative and E4 heterozygote and full population was analyzed for this outcome measure. A hierarchical testing procedure was used to control for the two rosiglitazone dose groups and the genetic subgroups.
Time frame: Baseline (Week 0) and Week 48
Population: ITT population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4 | All except E4/E4s | 1.5 Score on a scale | Standard Error 0.14 |
| Placebo | Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4 | APOE4 negatives | 1.3 Score on a scale | Standard Error 0.21 |
| Placebo | Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4 | Full population | 1.6 Score on a scale | Standard Error 0.14 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4 | All except E4/E4s | 1.0 Score on a scale | Standard Error 0.12 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4 | APOE4 negatives | 0.8 Score on a scale | Standard Error 0.16 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4 | Full population | 1.0 Score on a scale | Standard Error 0.12 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4 | APOE4 negatives | 1.5 Score on a scale | Standard Error 0.2 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4 | Full population | 1.7 Score on a scale | Standard Error 0.13 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4 | All except E4/E4s | 1.7 Score on a scale | Standard Error 0.14 |
p-value: =0.05695% CI: [-1, 0]Mixed Models Analysis
p-value: =0.58795% CI: [-0.4, 0.7]Mixed Models Analysis
p-value: =0.00495% CI: [-0.9, -0.2]Mixed Models Analysis
p-value: =0.40295% CI: [-0.2, 0.6]Mixed Models Analysis
p-value: =0.00295% CI: [-0.9, -0.2]Mixed Models Analysis
p-value: =0.47895% CI: [-0.2, 0.5]Mixed Models Analysis
Secondary
Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48
ADAS is a performance-based test that measures specific cognitive and behavioral dysfunctions in patients with Alzheimer's Disease. The cognitive subscale of the ADAS (ADAS-Cog) comprises 11 items that are summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. Change from baseline is calculated as endpoint value minus the baseline value.
Time frame: Baseline (Week 0), Week 8, 16, 24, 36 and 48
Population: ITT population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 36 | 1.8 Score on a scale | Standard Deviation 6.08 |
| Placebo | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 24 | 1.0 Score on a scale | Standard Deviation 5.86 |
| Placebo | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 8 | -0.2 Score on a scale | Standard Deviation 4.21 |
| Placebo | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 16 | -0.1 Score on a scale | Standard Deviation 5.09 |
| Placebo | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 48 | 2.9 Score on a scale | Standard Deviation 6.85 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 24 | -0.2 Score on a scale | Standard Deviation 5.17 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 8 | -0.6 Score on a scale | Standard Deviation 4.57 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 16 | -0.5 Score on a scale | Standard Deviation 4.76 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 36 | 1.3 Score on a scale | Standard Deviation 5.79 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 48 | 2.1 Score on a scale | Standard Deviation 6.25 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 48 | 2.6 Score on a scale | Standard Deviation 6.76 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 36 | 2.2 Score on a scale | Standard Deviation 6.4 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 8 | -0.2 Score on a scale | Standard Deviation 4.44 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 24 | 0.8 Score on a scale | Standard Deviation 5.66 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48 | Week 16 | 0.1 Score on a scale | Standard Deviation 5.13 |
p-value: 0.10595% CI: [-1.6, 0.2]ANCOVA
p-value: 0.48395% CI: [-1.3, 0.6]ANCOVA
Secondary
Change From Baseline in Alzheimer's Carer Quality of Life Instrument (ACQLI) Total Score
The ACQLI was an assessment of caregiver quality of life. This instrument consists of 30 questions exploring various aspects of carer's quality of life. Each of the questions had a two point response and the 30 questions were summed to provide a total score. Items are assumed to be unidimensional (i.e., represent a single variable) and are scored 0/1 (false/true) before summation into a total score with a 0-30 range. The total score ranged from 0 to 30, where 0 indicated absence of symptoms and higher score indicated worse outcomes; a negative change from baseline indicated improvement. Change from baseline was calculated as endpoint value minus the baseline value.
Time frame: Baseline (Week 0), Week 12, 36 and 48
Population: ITT population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Alzheimer's Carer Quality of Life Instrument (ACQLI) Total Score | Week 36 | 1.0 Score on a scale | Standard Error 0.28 |
| Placebo | Change From Baseline in Alzheimer's Carer Quality of Life Instrument (ACQLI) Total Score | Week 12 | 0.5 Score on a scale | Standard Error 0.23 |
| Placebo | Change From Baseline in Alzheimer's Carer Quality of Life Instrument (ACQLI) Total Score | Week 48 | 1.2 Score on a scale | Standard Error 0.3 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Alzheimer's Carer Quality of Life Instrument (ACQLI) Total Score | Week 36 | 0.6 Score on a scale | Standard Error 0.27 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Alzheimer's Carer Quality of Life Instrument (ACQLI) Total Score | Week 12 | -0.2 Score on a scale | Standard Error 0.23 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Alzheimer's Carer Quality of Life Instrument (ACQLI) Total Score | Week 48 | 0.3 Score on a scale | Standard Error 0.28 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Alzheimer's Carer Quality of Life Instrument (ACQLI) Total Score | Week 12 | -0.0 Score on a scale | Standard Error 0.22 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Alzheimer's Carer Quality of Life Instrument (ACQLI) Total Score | Week 48 | 1.1 Score on a scale | Standard Error 0.31 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Alzheimer's Carer Quality of Life Instrument (ACQLI) Total Score | Week 36 | 0.6 Score on a scale | Standard Error 0.26 |
p-value: 0.02795% CI: [-1.2, -0.1]Mixed Models Analysis
p-value: 0.09195% CI: [-1.1, 0.1]Mixed Models Analysis
p-value: 0.26895% CI: [-1.1, 0.3]Mixed Models Analysis
p-value: 0.31895% CI: [-1.1, 0.4]Mixed Models Analysis
p-value: 0.0395% CI: [-1.6, -0.1]Mixed Models Analysis
p-value: 0.79795% CI: [-0.9, 0.7]Mixed Models Analysis
Secondary
Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48
CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Change from baseline is calculated as endpoint value minus the baseline value.
Time frame: Baseline (Week 0), Week 12, 24, 36 and 48
Population: ITT population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48 | Week 12 | 0.4 Score on a scale | Standard Deviation 1.55 |
| Placebo | Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48 | Week 24 | 0.7 Score on a scale | Standard Deviation 2.01 |
| Placebo | Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48 | Week 36 | 1.0 Score on a scale | Standard Deviation 2.26 |
| Placebo | Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48 | Week 48 | 1.5 Score on a scale | Standard Deviation 2.68 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48 | Week 48 | 1.0 Score on a scale | Standard Deviation 2.28 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48 | Week 12 | 0.3 Score on a scale | Standard Deviation 1.36 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48 | Week 36 | 0.7 Score on a scale | Standard Deviation 2.06 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48 | Week 24 | 0.5 Score on a scale | Standard Deviation 1.67 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48 | Week 48 | 1.6 Score on a scale | Standard Deviation 2.56 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48 | Week 24 | 0.8 Score on a scale | Standard Deviation 1.83 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48 | Week 36 | 1.2 Score on a scale | Standard Deviation 2.3 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48 | Week 12 | 0.3 Score on a scale | Standard Deviation 1.4 |
p-value: 0.00495% CI: [-0.9, -0.2]ANCOVA
p-value: 0.55495% CI: [-0.3, 0.5]ANCOVA
Secondary
Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score
The DAD measures instrumental and basic activities of daily living in participants with Alzheimer's Disease (AD). This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. The scale includes 23 items relating to instrumental activities of daily living and 17 items relating to basic self-care. Each item can be scored as 1 = yes, 0 = no, non applicable = NA. Total score was obtained by adding the rating for each question and converting this total score out of 100. The total score ranged from 0 to 100, where higher score indicated better function and lower score indicated greater severity of symptoms; a positive change from baseline indicated an improvement. Change from baseline is calculated as endpoint value minus the baseline value.
Time frame: Baseline (Week 0), Week 8, 16, 24 and 48
Population: ITT population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score | At Week 8 | 0.1 Scores on a scale | Standard Error 0.56 |
| Placebo | Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score | At Week 16 | -1.6 Scores on a scale | Standard Error 0.62 |
| Placebo | Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score | At Week 24 | -3.5 Scores on a scale | Standard Error 0.69 |
| Placebo | Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score | At Week 48 | -7.8 Scores on a scale | Standard Error 0.82 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score | At Week 48 | -5.7 Scores on a scale | Standard Error 0.78 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score | At Week 8 | -0.5 Scores on a scale | Standard Error 0.48 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score | At Week 24 | -2.2 Scores on a scale | Standard Error 0.64 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score | At Week 16 | -1.6 Scores on a scale | Standard Error 0.59 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score | At Week 48 | -8.4 Scores on a scale | Standard Error 0.84 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score | At Week 16 | -2.1 Scores on a scale | Standard Error 0.56 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score | At Week 24 | -3.3 Scores on a scale | Standard Error 0.69 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score | At Week 8 | -1.1 Scores on a scale | Standard Error 0.47 |
p-value: =0.3495% CI: [-2, 0.7]Mixed Models Analysis
p-value: =0.07995% CI: [-2.5, 0.1]Mixed Models Analysis
p-value: =0.9195% CI: [-1.7, 1.5]Mixed Models Analysis
p-value: 0.52195% CI: [-2.1, 1]Mixed Models Analysis
p-value: =0.15495% CI: [-0.5, 3]Mixed Models Analysis
p-value: =0.83695% CI: [-1.6, 2]Mixed Models Analysis
p-value: 0.06195% CI: [-0.1, 4.2]Mixed Models Analysis
p-value: =0.56695% CI: [-2.9, 1.6]Mixed Models Analysis
Secondary
Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility
The EQ-5D Proxy is a two part scale that evaluated the participant's health status via Thermometer and Utility scores. The Thermometer score was the caregiver's rating of the participant's overall health status on a VAS (0 \[worst possible status\] to 100 \[best imaginable status\]). The Utility score was a caregiver rating of health status on dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression\] where '1' indicated better health state (no problems); '3' indicated worst health state (confined to bed). Total possible score was the sum of individual items, ranged from 5 to 15; lower score indicated a better health state and higher score indicated greater severity of symptoms. A positive change from baseline indicated improvement in the Thermometer score and a negative change from baseline indicated improvement in the Utility score. Change from baseline is calculated as endpoint value minus the baseline value.
Time frame: Baseline (Week 0), Week 12, 36 and 48
Population: ITT population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Thermometer: Week 12 | 0.5 Score on a scale | Standard Error 0.84 |
| Placebo | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Thermometer: Week 36 | 0.8 Score on a scale | Standard Error 0.95 |
| Placebo | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Thermometer: Week 48 | -1.5 Score on a scale | Standard Error 1.05 |
| Placebo | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Utility: Week 12 | 0.01 Score on a scale | Standard Error 0.009 |
| Placebo | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Utility: Week 36 | -0.02 Score on a scale | Standard Error 0.011 |
| Placebo | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Utility: Week 48 | -0.04 Score on a scale | Standard Error 0.012 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Utility: Week 48 | -0.02 Score on a scale | Standard Error 0.011 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Thermometer: Week 12 | 0.3 Score on a scale | Standard Error 0.82 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Utility: Week 12 | 0.02 Score on a scale | Standard Error 0.009 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Utility: Week 36 | -0.01 Score on a scale | Standard Error 0.01 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Thermometer: Week 36 | -1.6 Score on a scale | Standard Error 0.97 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Thermometer: Week 48 | -0.3 Score on a scale | Standard Error 0.96 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Thermometer: Week 36 | -2.1 Score on a scale | Standard Error 1.03 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Thermometer: Week 48 | -2.4 Score on a scale | Standard Error 1.08 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Utility: Week 48 | -0.05 Score on a scale | Standard Error 0.013 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Utility: Week 12 | -0.01 Score on a scale | Standard Error 0.01 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Thermometer: Week 12 | -0.5 Score on a scale | Standard Error 0.94 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility | Utility: Week 36 | -0.04 Score on a scale | Standard Error 0.012 |
p-value: 0.91495% CI: [-2.3, 2]Mixed Models Analysis
p-value: 0.41595% CI: [-3.3, 1.4]Mixed Models Analysis
p-value: 0.06395% CI: [-4.9, 0.1]Mixed Models Analysis
p-value: 0.0395% CI: [-5.6, -0.3]Mixed Models Analysis
p-value: 0.39295% CI: [-1.5, 3.8]Mixed Models Analysis
p-value: 0.55795% CI: [-3.7, 2]Mixed Models Analysis
p-value: 0.3295% CI: [-0.01, 0.03]Mixed Models Analysis
p-value: 0.1895% CI: [-0.04, 0.01]Mixed Models Analysis
p-value: 0.49895% CI: [-0.02, 0.04]Mixed Models Analysis
p-value: 0.08195% CI: [-0.06, 0]Mixed Models Analysis
p-value: 0.07795% CI: [0, 0.06]Mixed Models Analysis
p-value: 0.6495% CI: [-0.04, 0.03]Mixed Models Analysis
Secondary
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 48
Blood samples of participants were collected for HbA1c assessment. HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. Change from Baseline in HbA1c was calculated as the value at Week 48 minus the value at Baseline.
Time frame: Baseline (Week 0) and Week 48
Population: ITT population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 48 | 0.14 Percentage of total hemoglobin | Standard Error 0.02 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 48 | 0.21 Percentage of total hemoglobin | Standard Error 0.02 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 48 | 0.18 Percentage of total hemoglobin | Standard Error 0.02 |
p-value: 0.00695% CI: [0.02, 0.12]ANCOVA
p-value: 0.1495% CI: [-0.01, 0.09]ANCOVA
Secondary
Change From Baseline in HbA1c at Week 12, Week 24 and Week 36
Blood samples of participants were collected for HbA1c assessment. HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. Change from Baseline in HbA1c was calculated as the value at time point minus the value at Baseline.
Time frame: Baseline (Week 0) and Week 12, 24 and 36
Population: Safety population. Week 12, Week 24 and Week 36 assessments of HbA1c were only needed in participants whose HbA1c was \>= 6.5% at screening or who had known Type 2 diabetes. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in HbA1c at Week 12, Week 24 and Week 36 | Week 24 | 0.07 Percent of total hemoglobin | Standard Deviation 0.401 |
| Placebo | Change From Baseline in HbA1c at Week 12, Week 24 and Week 36 | Week 12 | 0.01 Percent of total hemoglobin | Standard Deviation 0.336 |
| Placebo | Change From Baseline in HbA1c at Week 12, Week 24 and Week 36 | Week 36 | 0.20 Percent of total hemoglobin | Standard Deviation 0.4 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in HbA1c at Week 12, Week 24 and Week 36 | Week 24 | 0.12 Percent of total hemoglobin | Standard Deviation 0.422 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in HbA1c at Week 12, Week 24 and Week 36 | Week 12 | 0.14 Percent of total hemoglobin | Standard Deviation 0.634 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in HbA1c at Week 12, Week 24 and Week 36 | Week 36 | 0.19 Percent of total hemoglobin | Standard Deviation 0.43 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in HbA1c at Week 12, Week 24 and Week 36 | Week 12 | 0.16 Percent of total hemoglobin | Standard Deviation 0.407 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in HbA1c at Week 12, Week 24 and Week 36 | Week 36 | 0.15 Percent of total hemoglobin | Standard Deviation 0.526 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in HbA1c at Week 12, Week 24 and Week 36 | Week 24 | 0.06 Percent of total hemoglobin | Standard Deviation 0.551 |
Secondary
Change From Baseline in Hematocrit Values
Blood samples of participants were collected for Hematocrit . Change from baseline in Hematocrit was calculated as endpoint value minus the baseline value.
Time frame: Baseline (Week 0), Week 4, 8, 12, 16, 36 and 48
Population: Safety population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Hematocrit Values | Week 4 | -0.0007 litre | Standard Deviation 0.02133 |
| Placebo | Change From Baseline in Hematocrit Values | Week 16 | -0.0003 litre | Standard Deviation 0.02318 |
| Placebo | Change From Baseline in Hematocrit Values | Week 36 | -0.0037 litre | Standard Deviation 0.02246 |
| Placebo | Change From Baseline in Hematocrit Values | Week 48 | -0.0029 litre | Standard Deviation 0.02447 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Hematocrit Values | Week 48 | -0.0177 litre | Standard Deviation 0.02658 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Hematocrit Values | Week 4 | -0.0068 litre | Standard Deviation 0.02189 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Hematocrit Values | Week 36 | -0.0167 litre | Standard Deviation 0.02471 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Hematocrit Values | Week 16 | -0.0174 litre | Standard Deviation 0.0246 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Hematocrit Values | Week 48 | -0.0346 litre | Standard Deviation 0.03177 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Hematocrit Values | Week 16 | -0.0339 litre | Standard Deviation 0.02697 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Hematocrit Values | Week 36 | -0.0352 litre | Standard Deviation 0.02834 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Hematocrit Values | Week 4 | -0.0115 litre | Standard Deviation 0.01994 |
Secondary
Change From Baseline in Hemoglobin Values
Blood samples of participants were collected for Hemoglobin. Change from baseline in Hemoglobin was calculated as endpoint value minus the baseline value.
Time frame: Baseline (Week 0), Week 4, 16, 36 and 48
Population: Safety population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Hemoglobin Values | Week 4 | -0.4 grams per litre (g/L) | Standard Deviation 6.45 |
| Placebo | Change From Baseline in Hemoglobin Values | Week 16 | -0.6 grams per litre (g/L) | Standard Deviation 7.01 |
| Placebo | Change From Baseline in Hemoglobin Values | Week 36 | -2.0 grams per litre (g/L) | Standard Deviation 7.25 |
| Placebo | Change From Baseline in Hemoglobin Values | Week 48 | -1.9 grams per litre (g/L) | Standard Deviation 7.86 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Hemoglobin Values | Week 16 | -6.2 grams per litre (g/L) | Standard Deviation 7.76 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Hemoglobin Values | Week 36 | -6.4 grams per litre (g/L) | Standard Deviation 8.04 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Hemoglobin Values | Week 4 | -2.5 grams per litre (g/L) | Standard Deviation 6.92 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Hemoglobin Values | Week 48 | -6.5 grams per litre (g/L) | Standard Deviation 8.45 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Hemoglobin Values | Week 36 | -12.5 grams per litre (g/L) | Standard Deviation 9.38 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Hemoglobin Values | Week 16 | -11.9 grams per litre (g/L) | Standard Deviation 8.65 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Hemoglobin Values | Week 48 | -12.2 grams per litre (g/L) | Standard Deviation 10.62 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Hemoglobin Values | Week 4 | -3.7 grams per litre (g/L) | Standard Deviation 6.19 |
Secondary
Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score
The NPI is a questionnaire that quantifies behavioral changes in dementia. For each of 12 behavioral domains there are 4 scores: Frequency (scale:1=occasionally to 4=very frequently), Severity (scale:1=Mild to 3=Severe), Total (frequency x severity), Caregiver distress (scale: 0=not at all distressing to 5=extremely distressing).The NPI Psychosis Subscale consists of the two domains of Delusions and Hallucinations, calculated by adding the Individual Item Scores, to yield a possible total score of 0 to 24. Lower score=less severity. Change from baseline is calculated as endpoint value minus the baseline value.
Time frame: Baseline (Week 0), Week 8, 16, 24 and 48
Population: ITT population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | At Week 8 | -0.3 Score on a scale | Standard Error 0.39 |
| Placebo | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | At Week 16 | -0.3 Score on a scale | Standard Error 0.43 |
| Placebo | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | At Week 24 | 0.4 Score on a scale | Standard Error 0.47 |
| Placebo | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | At Week 48 | 1.6 Score on a scale | Standard Error 0.61 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | At Week 48 | 0.1 Score on a scale | Standard Error 0.44 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | At Week 8 | -0.7 Score on a scale | Standard Error 0.32 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | At Week 24 | -0.2 Score on a scale | Standard Error 0.39 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | At Week 16 | -0.6 Score on a scale | Standard Error 0.36 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | At Week 48 | 1.8 Score on a scale | Standard Error 0.55 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | At Week 16 | 0.1 Score on a scale | Standard Error 0.43 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | At Week 24 | 0.2 Score on a scale | Standard Error 0.48 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score | At Week 8 | -0.3 Score on a scale | Standard Error 0.39 |
p-value: =0.41495% CI: [-1.3, 0.5]Mixed Models Analysis
p-value: 0.93195% CI: [-1, 1.1]Mixed Models Analysis
p-value: 0.48595% CI: [-1.4, 0.7]Mixed Models Analysis
p-value: 0.5595% CI: [-0.8, 1.5]Mixed Models Analysis
p-value: 0.26495% CI: [-1.8, 0.5]Mixed Models Analysis
p-value: 0.73295% CI: [-1.5, 1]Mixed Models Analysis
p-value: 0.04395% CI: [-2.9, 0]Mixed Models Analysis
p-value: 0.81495% CI: [-1.4, 1.8]Mixed Models Analysis
Secondary
Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD)
The RUD instrument was developed as a comprehensive tool to assess the amount of resource use among demented patients. RUD assessd both formal and informal resource use of the patient and the primary caregiver, making it possible to calculate costs from a societal perspective. Q1 corresponds to the number of hours during the last month the caregiver spent assisting the patient with toilet visits, eating, dressing, grooming, walking and bathing and Q2 corresponds to the number of hours during the last month the caregiver spent assisting the patient with shopping, food preparation, housekeeping, laundry, transportation, taking medication and managing financial matters. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented.
Time frame: Baseline (Week 0), Week 12, 24, 36 and 48
Population: ITT population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q1: Week 12 | 1.6 hours | Standard Error 2.25 |
| Placebo | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q1: Week 24 | 10.7 hours | Standard Error 3.52 |
| Placebo | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q1: Week 36 | 16.3 hours | Standard Error 3.6 |
| Placebo | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q1: Week 48 | 21.7 hours | Standard Error 4.16 |
| Placebo | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q2: Week 12 | -6.4 hours | Standard Error 4.64 |
| Placebo | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q2: Week 24 | 0.3 hours | Standard Error 4.89 |
| Placebo | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q2: Week 36 | 5.0 hours | Standard Error 5.34 |
| Placebo | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q2: Week 48 | 10.8 hours | Standard Error 5.51 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q1: Week 36 | 10.0 hours | Standard Error 3.43 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q2: Week 36 | 4.6 hours | Standard Error 4.44 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q1: Week 48 | 17.0 hours | Standard Error 4.17 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q2: Week 12 | 2.4 hours | Standard Error 4.16 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q2: Week 24 | 1.6 hours | Standard Error 4.17 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q1: Week 12 | 2.4 hours | Standard Error 2.5 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q1: Week 24 | 3.4 hours | Standard Error 1.84 |
| 2mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q2: Week 48 | 8.4 hours | Standard Error 4.88 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q1: Week 36 | 15.2 hours | Standard Error 4.95 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q1: Week 24 | 7.0 hours | Standard Error 4.06 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q1: Week 12 | -0.1 hours | Standard Error 3.18 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q1: Week 48 | 18.1 hours | Standard Error 4.72 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q2: Week 36 | 13.3 hours | Standard Error 5.35 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q2: Week 24 | 6.5 hours | Standard Error 4.88 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q2: Week 12 | 1.5 hours | Standard Error 4.5 |
| 8mg Rosiglitazone Extended Release | Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD) | Q2: Week 48 | 27.0 hours | Standard Error 6.24 |
Comparison: Week 12 Q1p-value: 0.78995% CI: [-5.2, 6.9]Mixed Models Analysis
p-value: 0.64395% CI: [-9, 5.6]Mixed Models Analysis
p-value: 0.05295% CI: [-14.7, 0.1]Mixed Models Analysis
p-value: 0.48195% CI: [-14, 6.6]Mixed Models Analysis
p-value: 0.19595% CI: [-15.6, 3.2]Mixed Models Analysis
p-value: 0.85795% CI: [-12.9, 10.7]Mixed Models Analysis
p-value: 0.42295% CI: [-15.9, 6.7]Mixed Models Analysis
p-value: 0.56295% CI: [-15.7, 8.6]Mixed Models Analysis
p-value: 0.12995% CI: [-2.6, 20.2]Mixed Models Analysis
p-value: 0.19495% CI: [-4, 19.9]Mixed Models Analysis
p-value: 0.83295% CI: [-10.5, 13.1]Mixed Models Analysis
p-value: 0.35195% CI: [-6.8, 19.1]Mixed Models Analysis
p-value: 0.94995% CI: [-13.3, 12.5]Mixed Models Analysis
p-value: 0.25395% CI: [-6, 22.6]Mixed Models Analysis
p-value: 0.73595% CI: [-16.2, 11.4]Mixed Models Analysis
p-value: 0.04695% CI: [0.3, 32]Mixed Models Analysis
Secondary
Change From Screening in Mini Mental State Examination (MMSE) Total Score
The MMSE consists of 11 tests of orientation, memory (recent and immediate), concentration, language and praxis. The scale was completed by the investigator, based on the performance of the participant, and took approximately 5 to 10 minutes to administer. The scores from 11 tests were combined to obtain the total score. The total scores range from 0 to 30, with lower scores indicating greater cognitive impairment and higher score indicating better outcome; a positive change from screening indicated an improvement. The total MMSE score for participants at screening was between 10 and 26, inclusive, in order to be eligible to participate in the trial. Change from screening is calculated as endpoint value minus the screening value.
Time frame: Screening (Week -4) and Week 48
Population: ITT population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Screening in Mini Mental State Examination (MMSE) Total Score | -1.6 Score on a scale | Standard Error 0.21 |
| 2mg Rosiglitazone Extended Release | Change From Screening in Mini Mental State Examination (MMSE) Total Score | -1.6 Score on a scale | Standard Error 0.2 |
| 8mg Rosiglitazone Extended Release | Change From Screening in Mini Mental State Examination (MMSE) Total Score | -1.7 Score on a scale | Standard Error 0.21 |
p-value: 0.61795% CI: [-0.7, 0.4]ANCOVA
p-value: 0.8795% CI: [-0.5, 0.6]ANCOVA
Secondary
Change in ADAS-Cog Total Score for Observed Cases at Week 54 Compared to Week 48
ADAS is a performance-based test that measures specific cognitive and behavioral dysfunctions in patients with Alzheimer's Disease. The cognitive subscale of the ADAS (ADAS-Cog) comprises 11 items that are summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. Change was calculated as endpoint value (Week 54) minus Week 48 value.
Time frame: Week 48 and 54
Population: ITT population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change in ADAS-Cog Total Score for Observed Cases at Week 54 Compared to Week 48 | 0.7 Score on a scale | Standard Error 0.28 |
| 2mg Rosiglitazone Extended Release | Change in ADAS-Cog Total Score for Observed Cases at Week 54 Compared to Week 48 | 1.1 Score on a scale | Standard Error 0.27 |
| 8mg Rosiglitazone Extended Release | Change in ADAS-Cog Total Score for Observed Cases at Week 54 Compared to Week 48 | 1.1 Score on a scale | Standard Error 0.29 |
p-value: 0.29295% CI: [-0.3, 1.1]ANCOVA
p-value: 0.29795% CI: [-0.3, 1.1]ANCOVA
Secondary
Change in CDR-SB Total Score at Week 54 Compared to Week 48
CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Change was calculated as endpoint value (Week 54) minus Week 48 value.
Time frame: Week 48 and 54
Population: ITT population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change in CDR-SB Total Score at Week 54 Compared to Week 48 | 0.2 Score on a scale | Standard Error 0.07 |
| 2mg Rosiglitazone Extended Release | Change in CDR-SB Total Score at Week 54 Compared to Week 48 | 0.2 Score on a scale | Standard Error 0.07 |
| 8mg Rosiglitazone Extended Release | Change in CDR-SB Total Score at Week 54 Compared to Week 48 | 0.1 Score on a scale | Standard Error 0.07 |
p-value: 0.59895% CI: [-0.2, 0.1]ANCOVA
p-value: 0.07395% CI: [-0.4, 0]ANCOVA
Secondary
Mean Change From Baseline in Heart Rate
Mean Change From Baseline in heart rate was calculated as endpoint value minus the baseline value.
Time frame: Baseline (Week 0), Week 4, 8, 12, 16, 24, 36, 48 and 56
Population: Safety population. Only those participants available at the specified time points were analyzed. Data for Site 040449 was not included in analysis due to audit finding.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Mean Change From Baseline in Heart Rate | Week 4 | 0.8 beats per min (bpm) | Standard Deviation 8.42 |
| Placebo | Mean Change From Baseline in Heart Rate | Week 8 | 1.5 beats per min (bpm) | Standard Deviation 8.98 |
| Placebo | Mean Change From Baseline in Heart Rate | Week 12 | 1.6 beats per min (bpm) | Standard Deviation 9.06 |
| Placebo | Mean Change From Baseline in Heart Rate | Week 16 | 1.0 beats per min (bpm) | Standard Deviation 9.23 |
| Placebo | Mean Change From Baseline in Heart Rate | Week 24 | 0.9 beats per min (bpm) | Standard Deviation 9.41 |
| Placebo | Mean Change From Baseline in Heart Rate | Week 36 | 0.9 beats per min (bpm) | Standard Deviation 9.3 |
| Placebo | Mean Change From Baseline in Heart Rate | Week 48 | 1.2 beats per min (bpm) | Standard Deviation 9.1 |
| Placebo | Mean Change From Baseline in Heart Rate | Week 54 | 0.5 beats per min (bpm) | Standard Deviation 10.1 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 12 | 1.8 beats per min (bpm) | Standard Deviation 9.04 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 48 | 1.4 beats per min (bpm) | Standard Deviation 8.92 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 16 | 1.3 beats per min (bpm) | Standard Deviation 9.18 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 24 | 1.3 beats per min (bpm) | Standard Deviation 8.7 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 36 | 1.8 beats per min (bpm) | Standard Deviation 9.42 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 4 | 1.1 beats per min (bpm) | Standard Deviation 7.95 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 8 | 1.3 beats per min (bpm) | Standard Deviation 9.19 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 54 | 1.4 beats per min (bpm) | Standard Deviation 9.55 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 12 | 0.7 beats per min (bpm) | Standard Deviation 9.68 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 8 | 1.0 beats per min (bpm) | Standard Deviation 8.91 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 4 | 0.6 beats per min (bpm) | Standard Deviation 8.36 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 16 | 0.8 beats per min (bpm) | Standard Deviation 9.52 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 48 | 0.7 beats per min (bpm) | Standard Deviation 9.43 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 36 | 1.1 beats per min (bpm) | Standard Deviation 9.58 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 24 | 0.8 beats per min (bpm) | Standard Deviation 10.19 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Heart Rate | Week 54 | 0.0 beats per min (bpm) | Standard Deviation 11.05 |
Secondary
Mean Change From Baseline in Short Term Memory Assessment Score
Short term memory assessment score was based on ADAS-Cog questionnaire (Question 1 and 7). ADAS is a performance-based test that measures specific cognitive and behavioral dysfunctions in participants with AD. Question 1 (Word Recall) and Question 7 (Word Recognition) of the ADAS-Cog questionnaire were summed to get a short term memory assessment score. Word recall task consist of the participants score was the mean number of words not recalled on three trials (maximum score 10) and word recognition task, to score this item the number of incorrect responses was counted (maximum error score was 12). The total score ranged from 0 to 22 with 0 indicating absence of symptoms and higher scores indicating greater dysfunction; a negative change from baseline indicated improvement. Change from Baseline in short term memory assessment was calculated as endpoint value minus the baseline value.
Time frame: Baseline (Week 0), Week 8, 16, 24, 36, 48 and 56
Population: ITT population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Mean Change From Baseline in Short Term Memory Assessment Score | Week 8 | -0.3 Score on a scale | Standard Deviation 2.71 |
| Placebo | Mean Change From Baseline in Short Term Memory Assessment Score | Week 16 | -0.4 Score on a scale | Standard Deviation 2.93 |
| Placebo | Mean Change From Baseline in Short Term Memory Assessment Score | Week 24 | 0.1 Score on a scale | Standard Deviation 2.96 |
| Placebo | Mean Change From Baseline in Short Term Memory Assessment Score | Week 36 | 0.4 Score on a scale | Standard Deviation 2.79 |
| Placebo | Mean Change From Baseline in Short Term Memory Assessment Score | Week 48 | 0.6 Score on a scale | Standard Deviation 3.01 |
| Placebo | Mean Change From Baseline in Short Term Memory Assessment Score | Week 54 | 1.1 Score on a scale | Standard Deviation 2.96 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Short Term Memory Assessment Score | Week 54 | 0.8 Score on a scale | Standard Deviation 3.1 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Short Term Memory Assessment Score | Week 8 | -0.4 Score on a scale | Standard Deviation 3.03 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Short Term Memory Assessment Score | Week 36 | 0.3 Score on a scale | Standard Deviation 3.18 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Short Term Memory Assessment Score | Week 48 | 0.3 Score on a scale | Standard Deviation 3.07 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Short Term Memory Assessment Score | Week 16 | -0.7 Score on a scale | Standard Deviation 2.92 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Short Term Memory Assessment Score | Week 24 | -0.4 Score on a scale | Standard Deviation 3.03 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Short Term Memory Assessment Score | Week 16 | -0.4 Score on a scale | Standard Deviation 3.07 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Short Term Memory Assessment Score | Week 24 | -0.1 Score on a scale | Standard Deviation 3.06 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Short Term Memory Assessment Score | Week 54 | 0.9 Score on a scale | Standard Deviation 3.17 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Short Term Memory Assessment Score | Week 36 | 0.7 Score on a scale | Standard Deviation 3.04 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Short Term Memory Assessment Score | Week 8 | -0.3 Score on a scale | Standard Deviation 2.76 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Short Term Memory Assessment Score | Week 48 | 0.4 Score on a scale | Standard Deviation 3.06 |
Secondary
Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP)
The plethysmographic method was used to measure BP throughout the study. Change in Systolic and Diastolic BP was calculated as endpoint value minus the baseline value.
Time frame: Baseline (Week 0), Week 4, 8, 12, 16, 24, 36, 48 and 56
Population: Safety population. Only those participants available at the specified time points were analyzed. Data for Site 040449 was not included in analysis due to audit finding.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 24 | -1.2 Millimeter of mercury (mmHg) | Standard Deviation 15.95 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 8 | -0.3 Millimeter of mercury (mmHg) | Standard Deviation 15.49 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 12 | -0.5 Millimeter of mercury (mmHg) | Standard Deviation 16.48 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 16 | -0.8 Millimeter of mercury (mmHg) | Standard Deviation 15.8 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 4 | -0.7 Millimeter of mercury (mmHg) | Standard Deviation 15.21 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 36 | -1.6 Millimeter of mercury (mmHg) | Standard Deviation 16.65 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 48 | -1.0 Millimeter of mercury (mmHg) | Standard Deviation 17.08 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 54 | 0.0 Millimeter of mercury (mmHg) | Standard Deviation 17.24 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 4 | -0.4 Millimeter of mercury (mmHg) | Standard Deviation 9.54 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 8 | -0.0 Millimeter of mercury (mmHg) | Standard Deviation 9.55 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 12 | 0.0 Millimeter of mercury (mmHg) | Standard Deviation 9.63 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 16 | -0.7 Millimeter of mercury (mmHg) | Standard Deviation 9.78 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 24 | -1.1 Millimeter of mercury (mmHg) | Standard Deviation 9.87 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 36 | -1.2 Millimeter of mercury (mmHg) | Standard Deviation 10.27 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 48 | -0.8 Millimeter of mercury (mmHg) | Standard Deviation 10.85 |
| Placebo | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 54 | -0.9 Millimeter of mercury (mmHg) | Standard Deviation 10.35 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 36 | -0.3 Millimeter of mercury (mmHg) | Standard Deviation 15.79 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 48 | -0.6 Millimeter of mercury (mmHg) | Standard Deviation 15.05 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 54 | -1.1 Millimeter of mercury (mmHg) | Standard Deviation 14.95 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 36 | -0.6 Millimeter of mercury (mmHg) | Standard Deviation 9.94 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 4 | -0.7 Millimeter of mercury (mmHg) | Standard Deviation 9.21 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 8 | -0.9 Millimeter of mercury (mmHg) | Standard Deviation 9.2 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 54 | -0.4 Millimeter of mercury (mmHg) | Standard Deviation 9.62 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 12 | -1.3 Millimeter of mercury (mmHg) | Standard Deviation 9.25 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 4 | -1.0 Millimeter of mercury (mmHg) | Standard Deviation 13.21 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 48 | -0.5 Millimeter of mercury (mmHg) | Standard Deviation 10.02 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 8 | -0.7 Millimeter of mercury (mmHg) | Standard Deviation 14.55 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 16 | -1.3 Millimeter of mercury (mmHg) | Standard Deviation 9.16 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 12 | -2.5 Millimeter of mercury (mmHg) | Standard Deviation 14.49 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 16 | -1.7 Millimeter of mercury (mmHg) | Standard Deviation 14.8 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 24 | -1.0 Millimeter of mercury (mmHg) | Standard Deviation 15.22 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 24 | -1.2 Millimeter of mercury (mmHg) | Standard Deviation 9.55 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 12 | -2.5 Millimeter of mercury (mmHg) | Standard Deviation 9.49 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 36 | -2.7 Millimeter of mercury (mmHg) | Standard Deviation 15.97 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 24 | -2.6 Millimeter of mercury (mmHg) | Standard Deviation 9.48 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 12 | -4.2 Millimeter of mercury (mmHg) | Standard Deviation 15.25 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 48 | -2.5 Millimeter of mercury (mmHg) | Standard Deviation 16.55 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 54 | -1.8 Millimeter of mercury (mmHg) | Standard Deviation 10.04 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 4 | -2.3 Millimeter of mercury (mmHg) | Standard Deviation 13.43 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 54 | -2.3 Millimeter of mercury (mmHg) | Standard Deviation 15.56 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 16 | -3.0 Millimeter of mercury (mmHg) | Standard Deviation 9.62 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 24 | -3.5 Millimeter of mercury (mmHg) | Standard Deviation 14.74 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 4 | -1.2 Millimeter of mercury (mmHg) | Standard Deviation 8.51 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 36 | -3.3 Millimeter of mercury (mmHg) | Standard Deviation 10.68 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 8 | -2.9 Millimeter of mercury (mmHg) | Standard Deviation 14.49 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 8 | -2.1 Millimeter of mercury (mmHg) | Standard Deviation 9.21 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Systolic BP Week 16 | -3.7 Millimeter of mercury (mmHg) | Standard Deviation 15.75 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) | Diastolic BP Week 48 | -1.9 Millimeter of mercury (mmHg) | Standard Deviation 11.07 |
Secondary
Mean Change From Baseline in Weight
Body weight was measured at all visits, without shoes and wearing light clothing. Mean Change From Baseline in Weight was calculated as endpoint value minus the baseline value.
Time frame: Baseline (Week 0), Week 4, 8, 12, 16, 24, 36, 48 and 56
Population: Safety population. Here, n=number of participants with observed data contributing to the analysis. Data for Site 040449 was not included in analysis due to audit finding.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Mean Change From Baseline in Weight | Week 4 | 0.1 kilogram (kg) | Standard Deviation 2.04 |
| Placebo | Mean Change From Baseline in Weight | Week 8 | 0.2 kilogram (kg) | Standard Deviation 2.35 |
| Placebo | Mean Change From Baseline in Weight | Week 12 | 0.2 kilogram (kg) | Standard Deviation 2.5 |
| Placebo | Mean Change From Baseline in Weight | Week 16 | 0.1 kilogram (kg) | Standard Deviation 2.88 |
| Placebo | Mean Change From Baseline in Weight | Week 24 | 0.1 kilogram (kg) | Standard Deviation 2.88 |
| Placebo | Mean Change From Baseline in Weight | Week 36 | 0.0 kilogram (kg) | Standard Deviation 3.37 |
| Placebo | Mean Change From Baseline in Weight | Week 48 | 0.4 kilogram (kg) | Standard Deviation 3.54 |
| Placebo | Mean Change From Baseline in Weight | Week 54 | 0.3 kilogram (kg) | Standard Deviation 3.74 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 12 | 0.3 kilogram (kg) | Standard Deviation 2.09 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 48 | 0.8 kilogram (kg) | Standard Deviation 3.47 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 16 | 0.3 kilogram (kg) | Standard Deviation 2.44 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 24 | 0.6 kilogram (kg) | Standard Deviation 2.77 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 36 | 0.7 kilogram (kg) | Standard Deviation 3 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 4 | 0.2 kilogram (kg) | Standard Deviation 1.66 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 8 | 0.3 kilogram (kg) | Standard Deviation 1.95 |
| 2mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 54 | 0.7 kilogram (kg) | Standard Deviation 3.69 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 12 | 0.9 kilogram (kg) | Standard Deviation 2.33 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 8 | 0.7 kilogram (kg) | Standard Deviation 2.37 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 4 | 0.3 kilogram (kg) | Standard Deviation 1.88 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 16 | 1.0 kilogram (kg) | Standard Deviation 2.56 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 48 | 1.3 kilogram (kg) | Standard Deviation 4.13 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 36 | 1.3 kilogram (kg) | Standard Deviation 3.92 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 24 | 0.9 kilogram (kg) | Standard Deviation 3.26 |
| 8mg Rosiglitazone Extended Release | Mean Change From Baseline in Weight | Week 54 | 0.8 kilogram (kg) | Standard Deviation 4.53 |
Secondary
Number of Participants With Laboratory Potential Clinical Concern (PCC) Values
Only those parameters for which at least one value of clinical concern (CC) was reported are summarized. Pre-defined limits of potential clinical concern (CC Low \[relative to the lower limit of normal\], CC High \[relative to the upper limit of normal\]) are: Hematocrit 0.8, 1.2; hemoglobin 10-11, 16.5-18; Red blood corpuscles(RBC) 0.8, 1.2; mean corpuscular volume (MCV) 0.8, 1.2; mean corpuscular hemoglobin (MCH) 0.8, 1.2; White blood corpuscles (WBC) 3- absolute value, 15-absolute value, Red Cell Distribution Width (RDW) 0.8, 1.2; Lymphocytes 0.75, 1.5; Monocytes NA, 2; Eosinophil NA, 2; platelet count 100-absolute, 500-absoulte; segmented neutrophil (SN) 0.75, 1.5 and Total Neutrophil (TN) 0.75, 1.5.
Time frame: Baseline (Week 0), Week 4, 8, 12, 16, 24, 36, 48 and 56
Population: Safety population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | TN low | 2 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | RBC low | 0 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Mean CV high | 0 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Hemoglobin low | 8 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | RBC high | 0 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Mean CV low | 2 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | WBC low | 1 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | RDW high | 18 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Monocytes low | 81 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | TN high | 4 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Platelet count low | 1 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Platelet count high | 4 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Lymphocytes high | 0 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | WBC high | 4 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | SN low | 2 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Lymphocytes low | 8 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Hemoglobin high | 2 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Eosinophils high | 0 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Mean CH high | 0 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Hematocrit low | 2 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | SN high | 8 participants |
| Placebo | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Mean CH low | 2 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | SN high | 2 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Eosinophils high | 3 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Hematocrit low | 2 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Hemoglobin high | 0 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Hemoglobin low | 11 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Lymphocytes high | 1 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Lymphocytes low | 10 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Mean CH high | 0 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Mean CH low | 2 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Mean CV high | 0 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Mean CV low | 1 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Monocytes low | 55 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Platelet count high | 2 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Platelet count low | 2 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | RDW high | 31 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | RBC high | 1 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | RBC low | 1 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | SN low | 6 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | TN high | 1 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | TN low | 6 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | WBC high | 1 participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | WBC low | 5 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | RBC high | 0 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Mean CH low | 0 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Hematocrit low | 5 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | RBC low | 8 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Mean CH high | 1 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Lymphocytes low | 13 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | SN high | 4 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Lymphocytes high | 2 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | WBC low | 12 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | SN low | 13 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Hemoglobin low | 31 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | WBC high | 3 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | TN high | 2 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Platelet count high | 7 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Monocytes low | 65 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Hemoglobin high | 0 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Platelet count low | 4 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Mean CV low | 0 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Eosinophils high | 0 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | RDW high | 86 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | Mean CV high | 1 participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Laboratory Potential Clinical Concern (PCC) Values | TN low | 13 participants |
Secondary
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An adverse event (AE) was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. The data was reported for prospective period.
Time frame: Up to Week 54
Population: The safety population included all participants randomized to treatment and received at least one dose of study medication.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any TEAEs | 304 Participants |
| Placebo | Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAEs | 62 Participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any TEAEs | 273 Participants |
| 2mg Rosiglitazone Extended Release | Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAEs | 45 Participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any TEAEs | 327 Participants |
| 8mg Rosiglitazone Extended Release | Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Any SAEs | 50 Participants |